HIV合并或未合并慢性HBV感染者启动ART后肝脏硬度变化
尼日利亚前瞻性纵向研究纳入106例HIV和71例HIV/HBV感染未治成人,启动ART后第3年用瞬时弹性成像评估肝硬度。HIV/HBV组基线肝硬度和下降幅度更高,41%肝纤维化分期回退至少1级,高于HIV组的17%(P<0.01);第3年两组肝硬度无显著差异。基线CD4≥200 cells/mm3和较低BMI与肝硬度分期下降相关。
要点
- HIV/HBV合并感染者ART后肝纤维化回退比例高于单纯HIV感染者。
- ART启动3年后两组肝硬度值无显著差异。
- 基线CD4≥200 cells/mm3和较低BMI与肝硬度分期下降相关。
核心结论
- HBV合并感染不削弱HIV感染者启动ART后肝硬度下降,尽管治疗前是更晚期肝病的危险因素。
研究设计与样本
- 前瞻性纵向研究,2011年7月至2015年2月在尼日利亚Jos大学教学医院HIV治疗中心纳入未治HIV和HIV/HBV感染成人(≥18岁),启动ART并在基线和第3年行瞬时弹性成像。
- 共分析106例HIV感染和71例HIV/HBV感染患者,70.5%为女性,中位年龄34岁(IQR 29-42岁)。
- 肝硬度cut-off:中度纤维化5.9 kPa,进展性纤维化7.6 kPa,肝硬化9.4 kPa(对应Metavir评分)。
- 采用多变量回归分析肝硬度分期(≥1个Metavir分期)下降的相关因素。
主要发现
- HIV/HBV组基线肝硬度和中位肝硬度下降幅度均显著高于HIV组。
- HIV/HBV组41%患者肝纤维化分期回退至少1级,HIV组为17%(P<0.01)。
- 第3年时HIV组与HIV/HBV组肝硬度评分无显著差异。
- 多变量分析中,基线CD4+ T细胞≥200 cells/mm3(对比<200 cells/mm3)和较低BMI者更可能出现肝硬度分期下降。
关键数值与推荐
- 肝硬度cut-off:5.9 kPa为中度纤维化,7.6 kPa为进展性纤维化,9.4 kPa为肝硬化(Metavir评分)。
- 纤维化回退定义为肝硬度分期下降≥1个Metavir分期。
临床怎么用
- 对HIV合并HBV感染者启动ART后应监测肝纤维化,合并感染者在治疗前肝病更晚期但ART后肝硬度可下降。
- 基线CD4≥200 cells/mm3和较低BMI者肝硬度分期下降可能性更高,可据此识别需重点随访人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data from sub-Saharan Africa on long-term liver fibrosis changes in HIV- and HIV/HBV-infected individuals. OBJECTIVES: To assess the effects of ART on liver stiffness measurement (LSM) using transient elastography (TE) in HIV- and HIV/HBV-infected Nigerian adults and examine factors associated with fibrosis regression. METHODS: We included ART-naive HIV- and HIV/HBV-infected adults (≥18 years) enrolled in a prospective, longitudinal study of liver disease between July 2011 and February 2015 at Jos University Teaching Hospital HIV Care and Treatment Centre in Nigeria. Patients initiated ART and had TE at baseline and follow-up (year 3). LSM cut-offs for Metavir scores were 5.9, 7.6 and 9.4 kPa for moderate fibrosis, advanced fibrosis and cirrhosis, respectively. We used multivariable regression to identify factors associated with TE (≥1 Metavir) stage decline. RESULTS: A total of 106 HIV- and 71 HIV/HBV-infected patients [70.5% female and median age = 34 years (IQR = 29-42 years)] were studied. Baseline LSM and median LSM decline were significantly higher in HIV/HBV- versus HIV-infected patients; 41% of HIV/HBV-infected patients regressed ≥1 Metavir stage versus 17% of HIV-infected patients (P < 0.01); LSM scores at year 3 were not significantly different between HIV- and HIV/HBV-infected patients. In multivariable analyses, patients with baseline CD4+ T cells ≥200 (versus <200) cells/mm3 and lower BMIs were more likely to experience LSM stage decline. CONCLUSIONS: HBV coinfection does not attenuate LSM declines in HIV-infected patients after ART initiation despite being a risk factor for more advanced liver disease prior to therapy. The inverse association between BMI and TE stage decline needs further investigation.
引用
- Grant JL, Agaba P, Ugoagwu P, et al. Changes in liver stiffness after ART initiation in HIV-infected Nigerian adults with and without chronic HBV. J Antimicrob Chemother. 2019. PMID: 31225612. doi:10.1093/jac/dkz145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。